About this trial
This project aims to identify key cells and molecules involved in the development and modulation of neuropathic pain treated with spinal cord stimulation (SCS). By measuring concentrations of selected inflammatory mediators and signaling molecules (e.g., IL-1β, IL-6, IL-17, IL-33, BDNF, VEGF, GABA) in the blood and cerebrospinal fluid (CSF) of patients undergoing SCS, the study seeks to better understand the mechanism of action of SCS. The findings may allow the development of predictive biomarkers, help tailor stimulation parameters, and support complementary pharmacotherapy. The project also explores differences in response to various stimulation types and the role of glial cells in SCS efficacy, with a view to improving patient outcomes through more personalized neuromodulation strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18-80
PSPS or CRPS
Neuropathic pain for at least 6 months
Disqualifiers
Drug/alcohol addiction
Malignant tumour
Psychiatric disorders
Active infection
Trial design
Single group
Treatments tested in this trial
Immunological Factors
Diagnostic testAssessment of interleukins and other molecues in CSF and blood of patients with SCS.
Treatment groups
Trial outcomes
Primary outcomes
Oswestry Disability Index
Oswestry Disability Index before and after trial stimulation
Pain reduction
VAS
Secondary outcomes
Changes in blood and CSF inflammatory markers
Changes in blood and CSF inflammatory markers
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Pawel Sokal
Lead sponsor
Jan Biziel University Hospital No 2 in Bydgoszcz
Sponsor institution
Department of Neurosurgery Collegium Medicum Nicolaus Copernicus University
Collaborator
Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz
Collaborator